pipette
SWISS LABORATORY MEDICINE

Pipette 3-2019, S. 18

Kardiogenetik

Siv Fokstuen

Referenzen

1. Geisterfer-Lowrance AA et al. A molecular basis for familial hypertrophic cardiomyopathy : a beta myosin heavy chain gene missense mutation. Cell 1990 ;62 :999-1006
2. Curran ME et al. A molecular basis for cardiac arrythmia : HERG mutations cause long QT syndrome. Cell 1995 ; 80 :795-803.
3. Priori SG et al. HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrythmia syndromes. Europace 2013 ;15 :1389-406.
4. Elliott PM et al. 2014 ESC Guidlines on diagnosis and management of hypertrophic cardiomyopathy : the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 2014 ;35 :2733-79.
5. Richards S. et al : Standards and Guidlines for the Interpretation of Sequence Variants : A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015 ; 17(5) :405-424.
6. Gesetz über genetische Untersuchungen am Menschen. www.admin.ch
7. Maron BJ. Hypertrophic cardiomyopathy : a systematic review. JAMA 2002 ;287 :1308-20.
8. O'Mahony C et al. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM Risk-SCD). Eur Heart J 2014 ; 35 :2010-20.
9. Maron BJ et al. Genetics of hypertrophic cardiomyopathy after 20 years : clinical perspectives. J Am Coll Cardiol. 2012 ;60(8) :705-15.
10. Akhtar M, Elliott P. The genetics of hypertrophic cardiomyopathy. Global Cardiology Science & Practice. 2018 :36 https://doi.org/10.21542/gcsp.2018.36
11. Wordsworth S et al. DNA testing for hypertrophic cardiomyopathy : a cost-effectiveness model. Eur Heart J 2010 ;31 :926-935.